Scheduling, administration, biomarkers, and practical guidance.
Morning dosing within 30 min of waking. Receptor-preservation cycle prevents BDNF/TrkB downregulation; late-day dosing disrupts sleep architecture.
Intranasal is the lower-risk default route. Continuous multi-month use risks GABAergic tolerance; acute-stress dosing avoids the tolerance issue entirely.
Short half-life (5–10 min rodent) favours split dosing. Do not dose after 14:00 — sleep and BP disturbance are documented in the open-label human data.
Morning administration only — infusion is genuinely stimulating. Slow IV over 15–30 min to avoid arrhythmia. Contraindicated in severe renal failure.
Sits beneath the peptide stack rather than cycling alongside it. Standardised Cognizin® form is the most research-referenced. Higher 1,000 mg/day doses only under targeted clinical rationale.
Short half-life and mild activating profile make morning dosing optimal. Afternoon or evening dosing risks sleep-onset disruption even at standard dose.
Rodent half-life 5–10 min translates to a short human effective window. Splitting extends coverage without pushing dosing into sleep-disruptive hours; open-label data documents sleep disturbance with later dosing.
Manufacturer handbook is explicit: the infusion is stimulating and may cause excitability. Afternoon or evening administration risks insomnia even at standard 10 ml clinical dose.
For acute-stress use (presentations, exams, high-conflict meetings), dose window is tied to event onset rather than circadian timing. Continuous-cycle use defaults to morning dosing conventions of the stack.